Gilead Sciences, Inc. (GILD)
67
  • CONTENT
  • SOURCES
Remdesivir: EU-Staaten sollen ab Oktober nachbestellen können - Gilead-Aktie dennoch im Minus
Dazu werde die EU-Kommission in den nächsten Tagen mit dem Hersteller Gilead Sciences einen Vertrag für gemeinsame Bezugsrechte abschliessen, sagte ein Kommissionssprecher am Dienstag. Remdesivir war am 3. Juli als erstes Mittel zur Behandlung von Covid-19 zugelassen…
Remdesivir: EU-Staaten sollen ab Oktober nachbestellen können - Gilead-Aktie vorbörslich fester
Dazu werde die EU-Kommission in den nächsten Tagen mit dem Hersteller Gilead Sciences einen Vertrag für gemeinsame Bezugsrechte abschliessen, sagte ein Kommissionssprecher am Dienstag. Remdesivir war am 3. Juli als erstes Mittel zur Behandlung von Covid-19 zugelassen…
Gilead Makes A Sizeable Bet On Immunomedics (NASDAQ:GILD)
GILD recently acquired IMMU for $21 billion. IMMU's Trodelvy has strong efficacy with metastatic triple-negative breast cancer.
Gilead and Galapagos' filgotinib OK'd in Europe for rheumatoid arthritis (NASDAQ:GILD)
As expected, the European Commission approves Gilead Sciences' (GILD -0.5%) and collaboration partner Galapagos NV's (GLPG +3.2%) Jyseleca (filgotinib) for
Neue Geschäftsführung bei GILEAD Sciences in Wien
Mit 1. September 2020 hat Dr. Amaya Echevarría die Stelle als Geschäftsführerin von Gilead Sciences in Wien angetreten. Die ausgebildete Ärztin übernimmt die Agenden von Dr. Clemens Schödl, der nach Stockholm übersiedelt um die Region Nordics von Gilead zu leiten. +++
Gilead Sciences: Debt Fueled Bottom (NASDAQ:GILD)
Gilead Sciences paid a hefty premium for Immunomedics. The breast cancer drug deal is expected to be accretive to EPS by 2023.
Gilead Sciences Prices $7.25 Billion of Senior Unsecured Notes
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the pricing of senior unsecured notes in an aggregate principal amount of $7.25 billion, in an underwritten, registered public offering, consisting of seven tranches: $500 million of floating rate notes maturing in 2021 (the “2021 floating rate notes”) $500 million of floating rate notes maturing in 2023 (the “2023 floating rate notes” and together with the 2021 floating rate notes, “the floating rate not
Gilead to pay $97 million to settle U.S. kickback probe
https://www.investing.com/news/stock-market-news/gilead-to-pay-97-million-to-settle-us-kickback-probe-2305239
The Week Ahead In Biotech: Conference Presentations, IPOs In The Mix
Biotech stocks found themselves among gains in the week ended Sept. 18, with conference presentations, IPO news flow and updates on coronavirus vaccine/antibody candidates catalyzing some strong moves. A big-ticket M&A was announced at the start of the week. Gilead Sciences Inc. (NASDAQ: GILD agreed to buy Immunomedics Inc. (NASDAQ: IMMU ), which has a commercial antibody drug conjugate in the market. Three biopharma companies and a dialysis equipment maker debuted on Wall Street, with the former group raising combined gross proceeds of $522 million. Here're the catalytic events for the unfolding week: Conferences 56th annual meeting of the European Association for the Study of Diabetes, or EASD: Sept. 21-25 2020 American Academy of Neurology Science Highlights: Sept. 23-24 14th annual Sickle Cell Disease Research and Educational Symposium and 43rd National Sickle Cell Disease Scientific Meeting (virtual event): Sept. 23-25 PDUFA Dates The FDA could announce its decision on Bausch Health Companies Inc's (NYSE: BHC ) NDA for EM-100, …
Opinion: Recording pregnant women’s alcohol use is straight out of Gilead
Policing women’s bodies like they do in Margaret Atwood’s ‘The Handmaid’s Tale’, is not the way to prevent Foetal Alcohol Spectrum Disorder
Gilead Sciences (GILD) earnings: expect 5% revenue growth
Gilead Sciences, Inc. (GILD) is announcing earnings on May 02, 2019. What should you expect?
Gilead Sciences (GILD) earnings preview: fighting competitive headwinds?
Gilead Sciences, Inc. (GILD) is expected to report earnings on July 25 after market close. What are GILD earnings expectations? What news will the market be watching out for?
Gilead (GILD): why this stock is undervalued
Gilead stock looks slightly undervalued at this point because the market is undervaluing Gilead’s HIV and oncology portfolios. What is the potential for this stock?
AbbVie (ABBV): Will The Stock Recover?
ABBV diverted the Rova-T program today—and that led to its stock price fall by 13%. When will the stock bounce back?
Top 6 Biotech Stocks For Traders
If you’re up for some speculative biotech trades, we are presenting the top 6 among our freshest picks of biotech stocks for the coming 12 months.
Follow Us